Coloplast CEO looks forward to pivotal launch

The medtech company Coloplast has a number of important studies in the pipeline, and the its President and CEO Kristian Villumsen calls the launch of a new catheter platform absolutely crucial for the company's future continence operations.

CEO at Coloplast Kristian Villumsen looks forward to trial with antibacterial catheter platform. | Photo: Coloplast / PR

Coloplast is launching several clinical trials around the New Year in both in the UK and Germany, including important studies testing a new digital ostomy solution that can warn users of leaks via a sensor, an implanted nerve stimulator against overactive bladder disorder and a new antibacterial catheter platform, as reported by Danish business daily Børsen.

For President and CEO at Coloplast Kristian Villumsen, the last trial involving the antibacterial catheter platform will be particularly crucial for the growth opportunities of Coloplast's continence division.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs